These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32959120)

  • 1. Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.
    Onishi N; Kataoka M
    Breast Cancer; 2021 Nov; 28(6):1195-1211. PubMed ID: 32959120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACR Appropriateness Criteria Breast Cancer Screening.
    Mainiero MB; Lourenco A; Mahoney MC; Newell MS; Bailey L; Barke LD; D'Orsi C; Harvey JA; Hayes MK; Huynh PT; Jokich PM; Lee SJ; Lehman CD; Mankoff DA; Nepute JA; Patel SB; Reynolds HE; Sutherland ML; Haffty BG
    J Am Coll Radiol; 2013 Jan; 10(1):11-4. PubMed ID: 23290667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of breast cancer screening with magnetic resonance imaging in community practice.
    Hill DA; Haas JS; Wellman R; Hubbard RA; Lee CI; Alford-Teaster J; Wernli KJ; Henderson LM; Stout NK; Tosteson ANA; Kerlikowske K; Onega T
    J Gen Intern Med; 2018 Mar; 33(3):275-283. PubMed ID: 29214373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and management of women with a family history of breast cancer: Practical guide for clinicians.
    Heisey R; Carroll JC
    Can Fam Physician; 2016 Oct; 62(10):799-803. PubMed ID: 27737975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    Shieh Y; Eklund M; Madlensky L; Sawyer SD; Thompson CK; Stover Fiscalini A; Ziv E; Van't Veer LJ; Esserman LJ; Tice JA;
    J Natl Cancer Inst; 2017 Jan; 109(5):. PubMed ID: 28130475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACR Appropriateness Criteria Breast Cancer Screening.
    Mainiero MB; Lourenco A; Mahoney MC; Newell MS; Bailey L; Barke LD; D'Orsi C; Harvey JA; Hayes MK; Huynh PT; Jokich PM; Lee SJ; Lehman CD; Mankoff DA; Nepute JA; Patel SB; Reynolds HE; Sutherland ML; Haffty BG
    J Am Coll Radiol; 2016 Nov; 13(11S):R45-R49. PubMed ID: 27814813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Screening, Mammography, and Other Modalities.
    Fiorica JV
    Clin Obstet Gynecol; 2016 Dec; 59(4):688-709. PubMed ID: 27741212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Liljegren A; von Wachenfeldt A; Azavedo E; Eloranta S; Grundström H; Ståhlbom AK; Sundbom A; Sundén P; Svane G; Ulitzsch D; Arver B
    Breast Cancer Res Treat; 2018 Apr; 168(3):655-666. PubMed ID: 29318406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harmonizing Breast Cancer Screening Recommendations: Metrics and Accountability.
    Lee CS; Moy L; Friedewald SM; Sickles EA; Monticciolo DL
    AJR Am J Roentgenol; 2018 Feb; 210(2):241-245. PubMed ID: 29045178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges With Identifying Indication for Examination in Breast Imaging as a Key Clinical Attribute in Practice, Research, and Policy.
    Weiss JE; Goodrich M; Harris KA; Chicoine RE; Synnestvedt MB; Pyle SJ; Chen JS; Herschorn SD; Beaber EF; Haas JS; Tosteson AN; Onega T;
    J Am Coll Radiol; 2017 Feb; 14(2):198-207.e2. PubMed ID: 27744009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.
    Helvie MA; Bevers TB
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1398-1404. PubMed ID: 30442738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    Vreemann S; Gubern-Mérida A; Schlooz-Vries MS; Bult P; van Gils CH; Hoogerbrugge N; Karssemeijer N; Mann RM
    Radiology; 2018 Feb; 286(2):443-451. PubMed ID: 29040037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of breast cancer screening in high-risk women in Japan.
    Tozaki M; Nakamura S
    Breast Cancer; 2021 Nov; 28(6):1181-1187. PubMed ID: 32627143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which risk model to use? Clinical implications of the ACS MRI screening guidelines.
    Ozanne EM; Drohan B; Bosinoff P; Semine A; Jellinek M; Cronin C; Millham F; Dowd D; Rourke T; Block C; Hughes KS
    Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):146-9. PubMed ID: 23093547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.